Baxter will conduct a new phase 3 trial of Gammagard

Tuesday 24 January 2012

Baxter International has announced that it will conduct a new phase 3 trial of the drug Gammagard Liquid 10% to evaluate its use for treatment of mild to moderate Alzheimer's disease. The new trial will begin in early 2012 and involve some 400 participants for an estimated three years.

For more information, please see www.baxter.com/press_room/press_releases/2012/01_23_12_gammagard.html